Search Results for "therapeutic"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

GRAPHICAL ABSTRACT: Zilebesiran as Add-On Therapy in Patients with Hypertension Inadequately Controlled with a Standard Antihypertensive Medication: Efficacy and Safety Results from the KARDIA-2 Study

Vutrisiran reduces all-cause mortality, cardiovascular mortality, and cardiovascular events in patients with transthyretin amyloid cardiomyopathy: Analysis from the HELIOS-B trial

Real-World Persistency on Tafamidis: An Analysis of US Insurance Claims Data

Cardiovascular Morbidity and Mortality Among ATTR-CM Patients Treated with Tafamidis in the US

ATTRv-PN Expert Opinion Slide Deck

Recommendations from a panel of experts for the diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States.

Health-related quality of life for patients with transthyretin amyloid cardiomyopathy: A real-world study in Europe, Canada and Japan

Baseline Characteristics of Patients with Transthyretin Cardiac Amyloidosis Enrolled in the Patisiran Expanded Access Program

KARDIA-3: zilebesiran as add-on therapy in adults with hypertension who have established cardiovascular disease or are at high cardiovascular risk

Zilebesiran in combination with a standard-of-care antihypertensive in patients with inadequately controlled hypertension: Primary results from the phase 2 KARDIA-2 study

Clinical Presentation and Treatment Landscape of Patients with Transthyretin Amyloidosis With Cardiomyopathy: A Real-world Study in Five European Countries and Japan

HELIOS-B 12-Month Results from the Open-Label Extension Period of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Hereditary ATTR Amyloidosis: A Closer Look at the V122I Variant External

V122I is the most common variant of hATTR amyloidosis in the United States and is most prevalent in patients of African American descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.

Impact of Baseline Heart Failure Severity on Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial: A Subgroup Analysis

Zilebesiran in combination with a standard-of-care antihypertensive in patients with inadequately controlled hypertension: Primary results from the phase 2 KARDIA-2 study

A Phase 2 Study Evaluating the Effects of Mivelsiran, an Investigational RNA Interference Therapeutic, on Hemorrhagic and Nonhemorrhagic Manifestations of Cerebral Amyloid Angiopathy

Impact of Zilebesiran, an Investigational RNA Interference Therapeutic Targeting Hepatic Angiotensinogen, on Renin–Angiotensin System Biomarkers in Patients with Mild-to-Moderate Hypertension

RNAi Data Navigator: Focus on Vutrisiran

This interactive PDF provides an overview of ATTR-CM and RNAi therapeutics, and offers a deep dive into the vutrisiran data in ATTR-CM from the HELIOS-B trial, including the primary and additional analyses. Alnylam's ongoing commitment to ATTR amyloidosis is reflected in a summary of the current pipeline and TRITON-CM study design.

Summary of RNA Interference

An overview of RNAi discovery, how RNAi works, and features of RNAi therapeutics

The Science of RNA interference (RNAi)

This slide deck provides an overview of the science of RNA interference (RNAi), including mechanism of action and delivery platforms.

Vutrisiran: Use with mRNA COVID-19 Vaccines

Standard response letter on use of mRNA COVID-19 vaccines in patients receiving vutrisiran.

ALN-HTT02: Phase 1b Study

Standard response letter on the phase 1 study of ALN-HTT02.

Vutrisiran: Technetium Scintigraphy

Standard response letter on vutrisiran and technetium scintigraphy data assessed in a subset of patients from the HELIOS-A study.

Givosiran: Hemin Use

Standard response letter on givosiran and hemin use. This medical information response contains clinical data from the ENVISION study.

Givosiran: Renal Effects

Standard response letter on renal effects observed with the use of givosiran.

NfL as a Biomarker in hATTR Amyloidosis Infographic.

Infographic companion to the article by Sato et al, "Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis", published in the journal Amyloid, 2023.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.

Search Results for "therapeutic"

ATTRv-PN Expert Opinion Slide Deck Recommendations from a panel of experts for the diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States.

Summary of RNA Interference An overview of RNAi discovery, how RNAi works, and features of RNAi therapeutics

The Science of RNA interference (RNAi) This slide deck provides an overview of the science of RNA interference (RNAi), including mechanism of action and delivery platforms.

Vutrisiran: Use with mRNA COVID-19 Vaccines Standard response letter on use of mRNA COVID-19 vaccines in patients receiving vutrisiran.

ALN-HTT02: Phase 1b Study Standard response letter on the phase 1 study of ALN-HTT02.

Vutrisiran: Technetium Scintigraphy Standard response letter on vutrisiran and technetium scintigraphy data assessed in a subset of patients from the HELIOS-A study.

Givosiran: Hemin Use Standard response letter on givosiran and hemin use. This medical information response contains clinical data from the ENVISION study.

Givosiran: Renal Effects Standard response letter on renal effects observed with the use of givosiran.

NfL as a Biomarker in hATTR Amyloidosis Infographic. Infographic companion to the article by Sato et al, "Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis", published in the journal Amyloid, 2023.